1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride

1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride serves two distinct and equally important roles in pharmaceutical science: it is a key synthetic intermediate in the manufacture of the highly potent neuromuscular blocker cisatracurium besylate, and it is officially recognized as Papaverine Hydrochloride EP Impurity C (dihydropapaverine hydrochloride) in the European Pharmacopoeia . In industrial pharmaceutical manufacturing, 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride undergoes reduction to the corresponding tetrahydroisoquinoline derivative, which is then elaborated through a series of transformations to yield the final cisatracurium besylate drug substance — a widely used agent for muscle relaxation during surgical procedures and mechanical ventilation . As a reference standard, 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride is an essential tool for analytical method development, impurity profiling, and stability monitoring of papaverine hydrochloride drug substance, supporting regulatory compliance for generic manufacturers worldwide . The synthetic utility of 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride extends beyond cisatracurium to the broader family of tetrahydroisoquinoline alkaloids and benzylisoquinoline derivatives, positioning this compound as a versatile gateway to multiple pharmaceutical targets.

Product Parameters

Why Cosperpharm?

When your cisatracurium synthesis depends on intermediate quality or your papaverine impurity profile requires regulatory-grade reference standards, Cosperpharm delivers the precision and reliability that pharmaceutical manufacturing demands.

Dual-purpose supply chain. Cosperpharm supplies 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride at two distinct quality levels: industrial-grade (≥98%) for synthetic intermediate use in cisatracurium manufacturing, and reference-grade (≥95%) for analytical standard applications as Papaverine Hydrochloride EP Impurity C. One compound, two quality streams — both backed by full documentation.

Documentation that respects your regulatory timeline. For analytical customers, each batch of reference-grade material is released with a Certificate of Analysis (COA) that includes HPLC purity data, melting point verification (202 °C), and residual solvent analysis — organized for direct insertion into method validation and stability study reports. For manufacturing customers, DMF-ready documentation packages, stability summaries, and custom quality agreements are available upon request.

Scalable volumes without lead time surprises. Whether you need 1g of reference standard for HPLC method development or 25kg of intermediate for a commercial production campaign, Cosperpharm maintains inventory flexibility to meet your timeline. Standard R&D quantities (1g–25g) ship within 5–7 business days; bulk quantities (100g–25kg) ship within 2–3 weeks. Expedited shipping is available for urgent requirements.

Technical support that understands both sides. Our process chemistry team can advise on the reduction of 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride to the corresponding tetrahydro derivative (CAS 6429-04-5) for cisatracurium synthesis, as well as on reverse-phase HPLC conditions for impurity profiling against the papaverine API peak.

Competitive pricing, transparent communication. By controlling synthesis through validated routes, Cosperpharm delivers pricing that respects your cost of goods. Volume discounts apply at kilogram scales, and we communicate lead times upfront — no surprises, just reliable supply.

FAQ

Q1:What are the primary applications of this compound?

A: This compound serves two distinct applications. As an intermediate in cisatracurium besylate manufacturing, it undergoes reduction to tetrahydropapaverine hydrochloride, which is then elaborated through additional synthetic steps to the final neuromuscular blocker drug substance. As an analytical reference standard, it is used as Papaverine Hydrochloride EP Impurity C for HPLC method validation, impurity profiling, forced degradation studies, and stability monitoring of papaverine hydrochloride API and finished drug product.

Q2:Is this compound hazardous?

A: According to available safety data, 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride is classified as Acute Toxicity Category 4 (Acute Tox. 4) with hazard statement H302: Harmful if swallowed . Signal word is Warning. Use in a well‑ventilated area (fume hood) with appropriate PPE — lab coat, safety goggles, and chemical‑resistant gloves. Avoid dust generation and inhalation of fine particles. Refer to the Safety Data Sheet (SDS) for complete safety information.

Application Scenarios

1.Cisatracurium Besylate API Manufacturing

As the key synthetic precursor to tetrahydropapaverine hydrochloride, this compound is an essential intermediate in the manufacture of cisatracurium besylate (Nimbex®) — a potent neuromuscular blocking agent used in over 50% of general anesthesia procedures requiring endotracheal intubation. The dihydroisoquinolinium salt is first reduced to the corresponding tetrahydro derivative, then elaborated through additional steps to yield the final drug substance .

2.Papaverine Hydrochloride EP Impurity C Reference Standard

Officially designated as Papaverine Hydrochloride EP Impurity C in the European Pharmacopoeia (EP), this compound is a mandatory reference standard for pharmaceutical quality control laboratories. Used for identifying and quantifying Impurity C in papaverine hydrochloride API and finished drug product during batch release testing, stability monitoring, and impurity profiling. Essential for EP monograph compliance.

3.ANDA / NDA Regulatory Filing Support

For generic manufacturers filing Abbreviated New Drug Applications (ANDA) for papaverine hydrochloride, the presence of a certified EP Impurity C reference standard in the analytical method validation package — including system suitability testing, specificity studies, and impurity profiling data — is a regulatory expectation. Cosperpharm provides DMF‑ready documentation, stability data, and method validation support to facilitate these filings.

4.Tetrahydroisoquinoline Scaffold for Drug Discovery

The dihydroisoquinoline core serves as a versatile entry point to the broader tetrahydroisoquinoline alkaloid family. Synthetic chemists can reduce 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride (CAS 5884-22-0) to tetrahydropapaverine (CAS 6429-04-5) in high yield, then further functionalize the scaffold to access lappaconitine analogs, berbamine derivatives, and other bioactive tetrahydroisoquinoline targets with potential applications in antiarrhythmic and anticancer drug discovery .

5.Analytical Method Development & Validation

Essential for developing, validating and transferring HPLC and UPLC methods for papaverine drug substance and drug product. Used for method optimization, selectivity assessment, LOD/LOQ determination, accuracy and precision studies, and robustness testing as part of ICH Q2(R1)-compliant method validation.

6.Forced Degradation & Stress Studies

Used as an impurity marker in forced degradation studies (oxidative, thermal, photolytic, hydrolytic and basic/acidic stress conditions) to monitor the formation of Impurity C as a degradation product and to confirm the stability‑indicating power of analytical methods for papaverine hydrochloride formulations.

Quality Control (QC) Batch Release Testing Routine QC testing in papaverine hydrochloride manufacturing relies on this impurity reference standard for batch release analytical testing, stability monitoring across shelf‑life studies and impurity level tracking across production campaigns to demonstrate batch‑to‑batch consistency.

7.Process Development & Scale‑Up

Pharmaceutical process chemists use this intermediate for reaction optimization (Pictet–Spengler conditions, reduction parameters), impurity mapping, and development of scalable commercial manufacturing routes for cisatracurium besylate. Cosperpharm provides characterization data and process support for seamless scale‑up from laboratory to pilot plant.

8.Contract Research Organization (CRO) Analytical Services

CROs and CDMOs conducting impurity profiling, method validation, analytical method transfer or stability studies for papaverine hydrochloride client programs rely on certified reference standards to deliver defensible data to their pharmaceutical clients.

Contact us

Now you need a supply partner who delivers 1-(3,4-Dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride with the purity, documentation, and reliability that keep your project moving forward. Cosperpharm is ready to support you at every stage.